"What's wrong with my monkey?" Ethical perspectives on germline transgenesis in marmosets.
The birth of the first transgenic primate to have inherited a transgene from its parents opens the possibility to set up transgenic marmoset colonies, as these monkeys are small and relatively easy to keep and breed in research facilities. The prospect of transgenic marmoset models of human disease, readily available in the way that transgenic laboratory mice are currently, prompts excitement in the scientific community; but the idea of monkeys being bred to carry diseases is also contentious. We structure an ethical analysis of the transgenic marmoset case around three questions: whether it is acceptable to use animals as models of human disease; whether it is acceptable to genetically modify animals; and whether these animals' being monkeys makes a difference. The analysis considers the prospect of transgenic marmoset studies coming to replace transgenic mouse studies and lesion studies in marmosets in some areas of research. The mainstream, broadly utilitarian view of animal research suggests that such a transition will not give rise to greater ethical problems than those presently faced. It can be argued that using marmosets rather than mice will not result in more animal suffering, and that the benefits of research will improve with a move to a species more similar in phylogenetic terms to humans. The biological and social proximity of monkeys and humans may also benefit the animals by making it easier for scientists and caretakers to recognize signs of suffering and increasing the human motivation to limit it. The animal welfare and research impacts of the transition to marmoset use will depend very much on the extent to which researchers take these issues seriously and seek to minimize animal harm and optimize human benefit.
Olsson
I Anna S
IA
Laboratory Animal Science, IBMC-Instituto de Biologia Molecular e Celular, Universidade do Porto, Rua do Campo Alegre 823, 4150-180 Porto, Portugal. olsson@ibmc.up.pt
Sandøe
Peter
P
D000818:Animals; D030801:Animals, Genetically Modified / Q000235:genetics*; D001675:Bioethics; D035843:Biomedical Research / Q000941:ethics*; D002144:Callithrix / Q000235:genetics*; D004195:Disease Models, Animal; D005818:Genetic Engineering / Q000941:ethics* / Q000379:methods; D005854:Germ Cells / Q000378:metabolism*; D006801:Humans; D019076:Transgenes / Q000235:genetics
Comp Med. 2003 Aug;53(4):383-92
14524414
Nature. 2009 May 28;459(7246):523-7
19478777
Science. 2001 Jan 12;291(5502):309-12
11209082
Trends Neurosci. 2007 Sep;30(9):433-9
17765332
Lab Anim. 2009 Apr;43 Suppl 1:1-47
19286892
Lab Anim. 2001 Apr;35(2):117-30
11315160
Theriogenology. 2006 Mar 15;65(5):992-1004
16253321
Altern Lab Anim. 2005 Apr;33(2):119-27
16180987
Lab Anim. 2008 Jul;42(3):277-83
18625582
New Sci. 1999 May 22;162(2187):26-31
11657970
Nature. 2009 May 28;459(7246):515-6
19478771
Neurosci Biobehav Rev. 2009 Jan;33(1):33-47
18773919
Neuropsychopharmacology. 2009 Jan;34(1):74-89
18830240
Bioethics. 1993 Oct;7(5):402-19
11656251
Science. 2007 Sep 21;317(5845):1680
17885114
Proc Natl Acad Sci U S A. 2001 May 8;98(10):5937-42
11331768